The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States
Abstract
Hepatotoxicity due to drugs, herbal or dietary supplements remains largely a clinical diagnosis based on meticulous history taking and exclusion of other causes of liver injury. In 2004, the U.S. Drug-Induced Liver Injury Network (DILIN) was created under the auspices of the U.S. National Institute of Diabetes and Digestive and Kidney Diseases with the aims of establishing a large registry of cases for clinical, epidemiological and mechanistic study. From inception, the DILIN has used an expert opinion process that incorporates consensus amongst three different DILIN hepatologists assigned to each case. It is the most well-established, well-described and vigorous expert opinion process for DILI to date, and yet it is an imperfect standard. This review will discuss the DILIN expert opinion process, its strengths and weaknesses, psychometric performance and future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An expert opinion approach has been considered the gold‐standard, although disagreements between experts have also questioned its validity.”
From Methods for causality assessment of idiosyncratic drug‐induced liver injury (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lead, Mercury, and Arsenic in US- and Indian-Manufactured Ayurvedic Medicines Sold via the Internet
Saper, R. B. (2008) · JAMA · doi:10.1001/jama.300.8.915 · Cited by 533
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Navarro, V. J., Barnhart, H., Bonkovsky, H. L., Davern, T., Fontana, R. J., Grant, L., Reddy, R. K., Seeff, L. B., Serrano, J., Sherker, A. H., et al. (2014) · Hepatology · doi:10.1002/hep.27317 · Cited by 418 · cited 1×
“Herbal and dietary supplements (HDS) present unique challenges to hepatotoxicity assessment and has risen in incidence within the DILIN [25,26].”
Daly, A. K., Aithal, G. P., Leathart, J. B. S., Swainsbury, R. A., Dang, T. S., & Day, C. P. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.023 · Cited by 348
Research works printed but not linked: 27
- Hoofnagle, 2004, Drug-induced liver injury network (DILIN), Hepatology, 40, 773, 10.1002/hep.20445 · DOI
- Fontana, 2009, Drug-Induced Liver Injury Network (DILIN) prospective study: Rationale, design and conduct, Drug Saf., 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
- Agarwal, 2010, Important elements for the diagnosis of drug-induced liver injury, Clin. Gastroenterol. Hepatol., 8, 463, 10.1016/j.cgh.2010.02.008 · DOI
- Davern, 2011, Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury, Gastroenterology, 141, 1665, 10.1053/j.gastro.2011.07.051 · DOI · Paper page
- Dalton, 2007, The role of hepatitis E virus testing in drug-induced liver injury, Aliment. Pharmacol. Ther., 26, 1429, 10.1111/j.1365-2036.2007.03504.x · DOI · Paper page
- Rockey, 2010, Causality assessment in drug-induced liver injury using a structured expert opinion process: Comparison to the Roussel-Uclaf causality assessment method, Hepatology, 51, 2117, 10.1002/hep.23577 · DOI · Paper page
- Maria, 1997, Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis, Hepatology, 26, 664, 10.1002/hep.510260319 · DOI · Paper page
- Lucena, 2001, Comparison of two clinical scales for causality assessment in hepatotoxicity, Hepatology, 33, 123, 10.1053/jhep.2001.20645 · DOI · Paper page
- Arimone, 2005, Agreement of expert judgment in causality assessment of adverse drug reactions, Eur. J. Clin. Pharmacol., 61, 169, 10.1007/s00228-004-0869-2 · DOI
- Arimone, 2007, Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions, Br. J. Clin. Pharmacol., 64, 482, 10.1111/j.1365-2125.2007.02937.x · DOI
- Hayashi, 2015, Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN), Liver Int., 35, 1623, 10.1111/liv.12540 · DOI · Paper page
- Danan, 1993, Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries, J. Clin. Epidemiol., 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
- Huang, 2003, Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis, Hepatology, 37, 924, 10.1053/jhep.2003.50144 · DOI · Paper page
- Lucena, 2008, Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury, Hepatology, 48, 588, 10.1002/hep.22370 · DOI · Paper page
- Ritchie, 2006, Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity, Clin. Infect. Dis., 43, 779, 10.1086/507101 · DOI
- Watanabe, 2003, A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus, Clin. Pharmacol. Ther., 73, 435, 10.1016/S0009-9236(03)00014-6 · DOI · Paper page
- Donaldson, 2008, Flucloxacillin-induced liver injury: The extended MHC 57.1 haplotype as a major risk factor, Hepatology, 48, 396A
- Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 · DOI · Paper page
- Phillips, 2013, Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa, J. Acquir. Immune Defic. Syndr., 62, e55, 10.1097/QAI.0b013e31827ca50f · doi:10.1097/qai.0b013e31827ca50f
- Singer, 2010, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury, Nat. Genet., 42, 711, 10.1038/ng.632 · DOI · Paper page
- Spraggs, 2011, HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer, J. Clin. Oncol., 29, 667, 10.1200/JCO.2010.31.3197 · DOI · Paper page
- Hirata, 2008, Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: A preliminary case-control study, Pharm. J., 8, 29
- Kleiner, 2013, Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations, Hepatology, 59, 661, 10.1002/hep.26709 · DOI · Paper page
- Teschke, 2013, Drug- and herb-induced liver injury in clinical and translational hepatology: Causality assessment methods, quo vadis?, J. Clin. Transl. Hepatol., 1, 59
- Navarro, 2014, Hepatotoxicity induced by herbal and dietary supplements, Semin. Liver Dis., 34, 172, 10.1055/s-0034-1375958 · DOI · Paper page
- Fleshner, 2005, Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors, J. Urol., 174, 636, 10.1097/01.ju.0000165187.31941.cd · DOI
- Rockey, 2015, Liver disorders that can masquerade as drug-induced liver injury, Hepatology, 62, 1149A
Cited by
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Drug-induced liver injury: recent advances in diagnosis and risk assessment
Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017) · Gut · doi:10.1136/gutjnl-2016-313369 · Cited by 438
Drug induced liver injury: an update
Garcia-Cortes, M., Robles-Diaz, M., Stephens, C., Ortega-Alonso, A., Lucena, M. I., & Andrade, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02885-1 · Cited by 286
A missense variant in PTPN22 is a risk factor for drug-induced liver injury
Cirulli, E. T., Nicoletti, P., Abramson, K., Andrade, R. J., Bjornsson, E. S., Chalasani, N., Fontana, R. J., Hallberg, P., Li, Y. J., Lucena, M. I., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.034 · Cited by 137
Danan, G., & Teschke, R. (2018) · Drug Safety · doi:10.1007/s40264-018-0654-2 · Cited by 75
Metadata
- Authors
- Hayashi, P.
- Affiliations
- University of North Carolina Liver Center, 8011 Burnett-Womack Building, Chapel Hill, NC 27599-8754, USA
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-02-04
- Volume
- 17
- Issue
- 2
- Pages
- 201
- ISSN
- 1422-0067
- Cited by
- 60
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.